Correlation Between Mesenchymal Circulating Tumor Cells and Prognosis of Urologic Malignancies: a Single-center Retrospective Analysis

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2023 Feb 13

PMID 36777844

Authors

Lingdian Wang

Degang Ding

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the correlation of circulating tumor cells (CTCs) and mesenchymal CTCs (M-CTCs) with clinical characteristics and survival of patients with urologic malignancies.

Methods: The clinical data of 52 patients with urinary system malignancy in Henan Provincial People's Hospital were retrospectively analyzed (40 cases of renal malignant tumor, 7 cases of prostate cancer, 3 cases of urothelial carcinoma, 1 case of testis cancer, and 1 case of penile cancer). The CTC counts of patients were collected, and the expression of epithelial-mesenchymal transition phenotype in CTCs was evaluated. The relationship of different types of CTC counts with tumor stage, location, size, metastasis, and differentiation, as well as their effect on progression-free survival (PFS) were analyzed.

Results: We detected CTCs in all patients with urinary system malignancy. The positive rates of epithelial CTCs (E-CTC), M-CTCs, and epithelial/mesenchymal CTCs (E/M-CTCs) were 34.62%, 26.92% and 94.23%, respectively. Total CTCs (T-CTCs), M-CTCs and E/M-CTCs were correlated with distant metastasis (=-3.052, -3.574, -2.898; all <0.005). M-CTC count was correlated with lymph node metastasis (=-3.125; =0.002). Furthermore, the presence of T-CTCs ≥13.5, M-CTC ≥0.5 or E/M-CTCs ≥9.5 per 5 ml of blood was correlated with worse PFS in patients with urinary system malignancy.

Conclusions: M-CTC and E/M-CTC counts correlate with the prognosis of patients with urinary system malignancy. Higher M-CTC and E/M-CTC counts are risk factors for worse prognosis in patients with urinary system malignancies. All in all, M-CTC count is a valuable tumor biomarker for urologic malignancies.

References

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

De Giorgi U, Mego M, Scarpi E, Giordano A, Giuliano M, Valero V . Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. Ther Adv Med Oncol. 2019; 11:1758835919866065. PMC: 6696837. DOI: 10.1177/1758835919866065. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Lomas D, Ahmed H . All change in the prostate cancer diagnostic pathway. Nat Rev Clin Oncol. 2020; 17(6):372-381. DOI: 10.1038/s41571-020-0332-z. View

Quan Q, Wang X, Lu C, Ma W, Wang Y, Xia G . Cancer stem-like cells with hybrid epithelial/mesenchymal phenotype leading the collective invasion. Cancer Sci. 2019; 111(2):467-476. PMC: 7004545. DOI: 10.1111/cas.14285. View

Yu T, Wang C, Xie M, Zhu C, Shu Y, Tang J . Heterogeneity of CTC contributes to the organotropism of breast cancer. Biomed Pharmacother. 2021; 137:111314. DOI: 10.1016/j.biopha.2021.111314. View

Gkountela S, Castro-Giner F, Szczerba B, Vetter M, Landin J, Scherrer R . Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding. Cell. 2019; 176(1-2):98-112.e14. PMC: 6363966. DOI: 10.1016/j.cell.2018.11.046. View

Ye Q, Ling S, Zheng S, Xu X . Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019; 18(1):114. PMC: 6607541. DOI: 10.1186/s12943-019-1043-x. View

Schuster E, Taftaf R, Reduzzi C, Albert M, Romero-Calvo I, Liu H . Better together: circulating tumor cell clustering in metastatic cancer. Trends Cancer. 2021; 7(11):1020-1032. PMC: 8541931. DOI: 10.1016/j.trecan.2021.07.001. View

10.

Mohme M, Riethdorf S, Pantel K . Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2016; 14(3):155-167. DOI: 10.1038/nrclinonc.2016.144. View

11.

Scher H, Armstrong A, Schonhoft J, Gill A, Zhao J, Barnett E . Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2021; 150:83-94. PMC: 8772024. DOI: 10.1016/j.ejca.2021.02.042. View

12.

Goldkorn A, Ely B, Quinn D, Tangen C, Fink L, Xu T . Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(11):1136-42. PMC: 3970171. DOI: 10.1200/JCO.2013.51.7417. View

13.

Scher H, Heller G, Molina A, Attard G, Danila D, Jia X . Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015; 33(12):1348-55. PMC: 4397279. DOI: 10.1200/JCO.2014.55.3487. View

14.

Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q . Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021; 6(1):404. PMC: 8606574. DOI: 10.1038/s41392-021-00817-8. View

15.

Chen J, Cao S, Cai Z, Zheng L, Wang Q . Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients. Cancer Biomark. 2017; 20(4):487-498. DOI: 10.3233/CBM-170315. View

16.

Nassar A, Mouw K, Jegede O, Shinagare A, Kim J, Liu C . A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer. 2019; 122(4):555-563. PMC: 7028947. DOI: 10.1038/s41416-019-0686-0. View

17.

Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D . Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013; 339(6119):580-4. PMC: 3760262. DOI: 10.1126/science.1228522. View

18.

Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M . Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. Eur Urol. 2016; 70(6):985-992. PMC: 5568108. DOI: 10.1016/j.eururo.2016.05.023. View

19.

Yang J, Cheng S, Zhang N, Jin Y, Wang Y . Liquid biopsy for ovarian cancer using circulating tumor cells: Recent advances on the path to precision medicine. Biochim Biophys Acta Rev Cancer. 2021; 1877(1):188660. DOI: 10.1016/j.bbcan.2021.188660. View

20.

Wang Z, Zhang P, Li H, Yang X, Zhang Y, Li Z . Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC. Cancer Biol Ther. 2018; 20(4):505-512. PMC: 6422478. DOI: 10.1080/15384047.2018.1537576. View